The ORCA (Observer-Reported Communication Ability) outcome measure
In 2018, FAST funded Dr. Bryce Reeve of Duke University to create a novel communication measurement tool as an outcome measure assessment of caregiver observ
News
FAST Awards Drs. Silverman (UC-Davis) and Duis (Children’s Hospital Colorado) Grant to Study Gait as an Outcome Measure for Angelman Syndrome
Movement disorders affect nearly all individuals with Angelman syndrome (AS), with the most common concerns being spasticity, ataxia (as observed in the majo
FAST update on the impact of Covid-19
While the world as we know it has changed, abruptly and dramatically, we at FAST want you to know that we are here and we continue to move forward in our mis
FAST funds pioneering infrastructure grant
FAST is thrilled to announce a grant to our continued partners and renowned scientists dedicated to advancing therapeutics for Angelman syndrome.
Virtually Unstoppable: A Global Experience
This year’s virtual Summit & Gala has proven that FAST truly is global. Over 1,700 people from 61 countries around the world tuned in to FAST&rsquo
FAST Conference Draws 20 Pharmaceutical Companies and Raises Over $2.2 Million for Research
Downers Grove, IL – December 7, 2020 – The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Virtually Unstoppable, their annual
The Next Frontier in FAST Funded Research
For 12 years FAST has been working diligently to fundraise, identify research opportunities, and wisely invest in science in order to develop real and effect
FAST Italy: educating the Italian community and contributing to global research
Benedetta Sirtori with son Pier Luigi Today, FAST Italy is proud that their country’s first clinical trial for Angelman syndrome (AS), Roche’s Tangelo tr
FAST Funds Dr. Albert J. Keung’s Creation of Cell Lines and Organoids of Class I Deleted Genes
The past decade has seen the development of exciting therapeutic candidates ranging from antisense oligonucleotides (ASOs) to gene replacement therapies, bot
FAST Awards Drs. Silverman (UC-Davis) and Duis (Children’s Hospital Colorado) Grant to Study Gait as an Outcome Measure for Angelman Syndrome
Movement disorders affect nearly all individuals with Angelman syndrome (AS), with the most common concerns being spasticity, ataxia (as observed in the majo
FAST Grant to Dr. Scott Dindot for Translational Research in a Pig Model of Angelman Syndrome
Like humans with Angelman syndrome (AS), mouse models of AS exhibit seizures, impaired cognition, abnormal sleep, and motor-defects; however, the expressivit
FAST Awards Grant to Dr. Yong-Hui Jiang at Yale University to Create Full Deletion Mouse Model
In 1997, Dr. Art Beaudet at Baylor College of Medicine determined that the lack of UBE3A gene expression caused Angelman syndrome (AS). Part of his finding